Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema.

Athanassios K GiarmoukakisStyliani V BlazakiGeorgios C BontzosArgyro D PlakaKonstantinos N SeliniotakisLarissa D IoannidiTsilimbaris K Miltiadis

Published in: Therapeutics and clinical risk management (2020)

Our outcomes strongly suggest that administrating nepafenac 0.3% drops on a twice-daily regimen could be a promising alternative for the management of postoperative CME. Additional studies are necessary to further validate our results.

Keyphrases

patients undergoing
physical activity
diabetic retinopathy
adipose tissue
metabolic syndrome
glycemic control
weight loss